Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982351 | 0.87 | PDK1 (0.31) | — | |
| SCHEMBL11450306 | 0.81 | NPC1 (0.48) | POLBNPC1ALDH1A1MAPK1CHRNB2 | |
| SCHEMBL3930168 | 0.81 | — | — | |
| SCHEMBL5559670 | 0.80 | POLB (0.36) | HTR7POLBNPC1ALDH1A1MAPK1 | |
| SCHEMBL11468691 | 0.80 | POLB (0.37) | HTR7POLBHPGDNPC1ALDH1A1 | |
| SCHEMBL11467404 | 0.80 | GAA (0.39) | HTR7POLBNPC1ALDH1A1MAPK1 | |
| SCHEMBL3927065 | 0.79 | — | — | |
| SCHEMBL13715956 | 0.79 | NPC1 (0.37) | HTR7POLBNPC1ALDH1A1MAPK1 | |
| SCHEMBL977073 | 0.78 | GRM2 (0.31) | HTR7NPC1 | |
| SCHEMBL6872127 | 0.78 | SMN1; SMN2 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015276-A1 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith | NESVADBA PETER | 2008-01-17 | — | — | US | claimed |
| US-20040082742-A1 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith | CIBA SPECIALTY CHEMICALS CORP. | 2004-04-29 | — | — | US | claimed |
| EP-1343827-A1 | N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINE COMPOUNDS, THEIR CORRESPONDING N-OXIDES AND CONTROLLED RADICAL POLYMERIZATION THEREWITH | Ciba SC Holding AG (CH) | 2003-09-17 | — | — | EP | claimed |
| WO-2002048205-A1 | N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINE COMPOUNDS, THEIR CORRESPONDING N-OXIDES AND CONTROLLED RADICAL POLYMERIZATION THEREWITH | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-06-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015276-A1 | N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith | ALKBH2, ALKBH3, ALKBH5 | HTR7 1799/4885POLB 500/4885HPGD 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.